Allocation Concealment

Allocation concealment is a procedural safeguard used in clinical trials to prevent the person enrolling participants from knowing or predicting the upcoming treatment assignment until the moment of allocation.^[3] It ensures that enrollment decisions cannot be influenced by foreknowledge of which treatment a participant will receive.

Allocation concealment is considered one of the most important protections against bias in randomized trials. If the person responsible for enrolling participants can predict or discover the next treatment assignment, they may consciously or unconsciously steer certain types of patients toward a preferred arm, undermining the purpose of randomization. Meta epidemiological research has found that trials with inadequate or unclear allocation concealment tend to report larger treatment effects than those with adequate concealment (about 7% larger on the odds ratio scale in one large analysis), suggesting that the absence of this safeguard inflates effect estimates.^[4] Cochrane's risk of bias tools assess allocation concealment explicitly (as its own domain in the original tool and within the randomization process domain of RoB 2)^[1][5], and the CONSORT 2025 statement asks authors to describe the mechanism used to conceal the allocation sequence.^[2]

The central principle is that the treatment assignment must be unknowable until the participant has been irrevocably enrolled in the trial. Several methods achieve this goal with varying degrees of effectiveness.

Central randomization is widely considered the gold standard. In this approach, the enrolling clinician contacts a centralized system, typically via telephone or a secure web platform, after confirming the participant's eligibility and obtaining informed consent. The system generates the treatment assignment only at that point, and the clinician has no way to predict or influence it. This method is especially effective in multicenter trials because it ensures uniform procedures across sites.

Sequentially numbered, opaque, sealed envelopes (SNOSE) represent a lower cost alternative. Each envelope contains a treatment assignment generated from a randomization sequence. Envelopes are numbered in order and opened sequentially as participants are enrolled. For this method to work, the envelopes must be truly opaque (not readable when held to light), tamper evident (showing signs of premature opening), and stored securely.^[3] Despite these precautions, envelopes are more susceptible to subversion than centralized systems and are generally recommended only when centralized randomization is not feasible.

Pharmacy controlled allocation is another common method, particularly in drug trials. The pharmacy receives the randomization list and dispenses the appropriate treatment based on the participant's assignment number, without revealing the allocation to the clinical team.

It is essential to distinguish allocation concealment from blinding. Allocation concealment operates before and during the randomization process, preventing selection bias at enrollment. Blinding operates after randomization, preventing performance and detection bias during the treatment and assessment phases. A trial can have adequate allocation concealment but no blinding (for example, in a surgical trial where the procedure is inherently visible), and vice versa.^[3]

Allocation concealment should be implemented in every randomized trial, regardless of whether the trial is blinded. It is particularly critical in open label trials, where the absence of blinding makes it even more important to prevent selection bias at the enrollment stage. Researchers designing trials should choose the strongest concealment method their resources allow, with centralized systems preferred over envelope based methods.

A common error is confusing allocation concealment with blinding and assuming that a blinded trial automatically has adequate concealment. These are distinct methodological safeguards that address different sources of bias at different time points. Another mistake is using inadequate envelope procedures, such as envelopes that are not opaque, not sequentially numbered, or stored in an accessible location where they could be opened in advance.

Researchers sometimes also fail to report their allocation concealment method in published trial reports, which makes it impossible for systematic reviewers to assess risk of bias. CONSORT 2025 asks for a description of the concealment mechanism (item 18), yet reporting remains incomplete across the literature.^[2] Finally, in some trials, the concealment mechanism is technically adequate but is undermined by operational failures, such as a centralized system that reveals the allocation before enrollment is confirmed.

A multicenter vaccine trial across 12 hospital sites uses a centralized web based randomization system. After confirming a participant's eligibility and obtaining written informed consent, the enrolling nurse logs into the secure platform and enters the participant's demographic and eligibility data. The system confirms enrollment and immediately displays the treatment assignment (vaccine or placebo). At no point can the nurse predict the assignment before enrollment is finalized. An audit at the end of the trial reveals 100% compliance with the concealment procedure across all sites.